Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2015 - 2026)

At the end of FY2025, Accumulated Expenses at Syndax Pharmaceuticals came in at $103.06 million, up 71.5% from FY2024.

• Accumulated Expenses has now increased for four consecutive years, with a five-year compound annual growth rate of 33.5% (FY2020 to FY2025).
• In earlier years, Accumulated Expenses was $60.1 million in FY2024 (+50.8%), $39.86 million in FY2023 (+64.2%), $24.28 million in FY2022 (+67.8%) and $14.47 million in FY2021 (-40.4%).
• The Q3 2026 figure marks the highest quarterly Accumulated Expenses in data going back to Q4 2015.
• Compared with a year earlier, Accumulated Expenses has increased for 14 straight quarters, with growth averaging 66.6% over the last eight quarters.
• The best year-over-year quarter for Accumulated Expenses over five years was Q2 2025 (growth of 165.1%); the worst was Q4 2021 (a decline of 40.4%).
• Per Business Quant data, SNDX's Accumulated Expenses in the three quarters before Q3 2026 was $94.3 million (Q2 2026), $74.84 million (Q1 2026) and $103.06 million (Q4 2025).